2019 American Transplant Congress
Hepatitis C Treatment and Transplant Outcomes in Liver Transplant Recipients with Hepatitis C Positive Donors
University of Maryland Medical Center, Baltimore, MD
*Purpose: With direct-acting antivirals for hepatitis C virus (HCV), transplant centers have expanded the donor pool with positive short term outcomes with early HCV treatment.…2019 American Transplant Congress
Multicenter Experience Evaluating Outcomes of HCV-Seropositive Donors to HCV-Seronegative Recipients Liver Transplantation
*Purpose: Grafts from hepatitis C virus (HCV)-seropositive donors can now be considered for liver transplant (LT) due to the advent of direct-acting antiviral agents (DAA).…2019 American Transplant Congress
Hepatitis C Positive Donor to Negative Recipient Kidney Transplantation: A Single Center Real World Experience
North Shore University Hospital, Manhasset, NY
*Purpose: Several small studies have shown that transplanting a hepatitis C virus (HCV) negative recipient with a HCV positive donor is feasible in a research…2019 American Transplant Congress
Real World Impact of HCV Viremic Solid Organs on Waitlist Times
*Purpose: The advent of direct acting antiviral agents (DAAs) has led to a paradigm shift in the approach to hepatitis C (HCV) infected organs. The…2019 American Transplant Congress
Rapid Growth of HCV-Infected Donors for HCV-Uninfected Kidney and Liver Transplant Recipients in the United States
Johns Hopkins University, Baltimore, MD
*Purpose: Several single-center reports of using HCV-viremic organs for HCV-uninfected recipients were recently published in the US. In light of recent DAA introduction, we sought…2019 American Transplant Congress
Timing, Duration, and Source of Hepatitis C Virus (HCV) Antibodies (Ab) among HCV-Negative Recipients of an Organ from an HCV-Infected Donor
1University of Pennsylvania, Philadelphia, PA, 2Abbott Labs, Chicago, IL
*Purpose: The opioid epidemic has increased the number of deceased donors with active (Ab+/NAT+) or prior (Ab+/NAT-) HCV infection. Increased utilization of these donor organs…2019 American Transplant Congress
Renal Outcomes from Expander-1: Pilot Study of HCV+ Donor Kidneys for HCV- Kidney Recipients
*Purpose: Direct acting antivirals (DAAs) have led to high cure rates (>95%) for hepatitis C. Utilization of HCV+ donor kidneys for patients with advanced kidney…2019 American Transplant Congress
REHANNA: Renal Transplants in Hepatitis C Negative Recipients with Nucleic Acid Positive Donors with Short Course Direct Acting Antiviral Prophylaxis
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: To mitigate the current organ shortage and underutilization of hepatitis C-infected deceased donor (HCV D+) organs, we evaluated the use of HCV D+ kidneys…2019 American Transplant Congress
Results from the LIVE-C Free Trial
*Purpose: Ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) has shown excellent results post-liver transplant. However, due to the poor tolerability of RBV, it is commonly…2019 American Transplant Congress
The Treatment of Hepatitis C Virus (HCV) with Direct Acting Antiviral (DAA) Treatment in the Post Orthotopic Liver Transplant (OLT) Patient is Safe and Efficacious
*Purpose: Chronic HCV is one of the leading causes for end stage liver disease and liver transplantation. Since their introduction, DAAs have revolutionized the treatment…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 28
- Next Page »